查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
女性不孕症診斷、治療的全球市場:2022-2028年
市場調查報告書
商品編碼
1215565

女性不孕症診斷、治療的全球市場:2022-2028年

Female Infertility Diagnosis and Treatment Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3個工作天內

價格

全球女性不孕症診斷、治療的市場規模在預測期間內預計以5.6％的年複合成長率成長。

各診斷中，子宮輸卵管造影 (HSG) 的部門今後數年保持大幅佔有率。唐氏症，ONTD等遺傳性疾病的盛行率增加，是促進該部門成長的顯著要素。還有非侵入性子宮輸卵管攝影 (HSG) 引進擴大到實驗室，也是在預測期間內推動部門的主要原因。

本報告提供全球女性不孕症診斷、治療的市場調查，市場概要，市場成長的各種影響因素分析，市場規模的變化、預測，各種區分、各地區/主要國家的明細，競爭環境，主要企業簡介等彙整資訊。

目錄

第1章 報告概要

第2章 市場概要、洞察

第3章 競爭情形

  • 主要企業分析
  • 主要策略分析
  • COVID-19對主要企業的影響

第4章 市場分析:各種類

  • 全球女性不孕症診斷、治療市場:各診斷
    • 排卵檢驗
    • 子宮輸卵管造影 (HSG)
    • 子宮鏡檢查
    • 影像檢查
    • 卵巢預備檢驗
    • 荷爾蒙等級檢驗
    • 遺傳基因檢驗
    • 其他 (腹腔鏡檢驗)
  • 全球女性不孕症診斷、治療市場:各治療
    • 藥物
    • 手術
    • 子宮內授精 (IUI)
    • 輔助生殖技術醫療 (ART)
  • 全球女性不孕症診斷、治療市場:各終端用戶
    • 醫院、診療所
    • 居家護理
    • 病理、診斷中心

第5章 地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 企業簡介

  • Cook Group Inc.
  • Eli Lilly & Co.
  • Esco Group
  • Fairhaven Health
  • Ferring B.V.
  • Fujifilm Irvine Scientific, Inc.
  • GlaxoSmithKline Plc.
  • Merck KGaA
  • Princeton BioMeditech Corp.
  • Tempest Therapeutics, Inc.
Product Code: OMR2026621

Title:Global Female Infertility Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Ovulation Testing, Hysterosalpingography (HSG), Hysteroscopy, Imaging Testing, Ovarian Reserve Testing, Hormonal Level Testing, Genetic Testing, and Others)by Treatment (Drugs, Surgery, Intrauterine Insemination (IUI), Assisted Reproductive Technology (ART)) by End User(Hospitals and Clinics, Homecare, and Pathology and Diagnostic Centers) Forecast 2022-2028.

The global female infertility diagnosis and treatment market is anticipated to grow at a significant CAGR of 5.6% during the forecast period (2021-2028). Infertility affects millions of people of reproductive age across the globe and has an impact on their families and communities. Infertility may cause in females or males. In males, infertility is most commonly caused by problems in the ejection of semen, absence or low levels of sperm, or abnormal shape. In female infertility may be caused by a range of abnormalities of the ovaries, uterus, fallopian tubes, and the endocrine system, and among others. A survey of 692 female surgeons published in JAMA Surgery in July 2021 found that 42% had suffered a pregnancy loss, more than double the rate of the overall population.

Moreover, a lack of trained personnel and the necessary equipment and infrastructure, and the currently high costs of treatment medicines, are major barriers even for countries that are actively addressing the needs of people with infertility, which in turn hinders the growth of the market.

The global female infertility diagnosis and treatment market is segmented on the basis of diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into the ovulation testing, ovarian reserve testing, hormonal level testing, hysterosalpingography (HSG), hysteroscopy, imaging testing, genetic testing, and others. Based on diagnosis, the hysterosalpingography (HSG) segment hold's a leading market share in coming years. The increasing prevalence of genetic disorders such as Down syndrome, ONTD, and other disorders are the prominent factor that drives the market growth. Moreover, the growing laboratory application of non-invasive, hysterosalpingography (HSG) is also considered a major factor that boosts the segments during the forecast period.

Geographically market is segmented into: North America, Europe, Asia Pacific, and the Rest of the World. The European region is anticipated to grow at the fastest rate, owing to the well sounded healthcare systems, and the region have the highest rate of diagnosis and treatment adoption among all other countries, resulting in a key region for the global female infertility diagnosis market.

The major companies serving the global female infertility diagnosis and treatment market are: Bayer AG, Church & Dwight Co. Inc., Genea Ltd., Pfizer Inc., Vitrolife Sweden AB , Esco Group, Fairhaven Health, Ferring B.V., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In January 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women's health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS). Under the terms of the agreement, both companies contribute to drug targets and set high-quality technology platforms to jointly develop innovative treatment options.

Research Methodology

The market study of the global female infertility diagnosis and treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Female Infertility Diagnosis And Treatment Market Research And Analysis By Diagnosis
  • Global Female Infertility Diagnosis And Treatment Market Research And Analysis By Treatment
  • Global Female Infertility Diagnosis And Treatment Market Research and Analysis by End User

The Report Covers:

  • Comprehensive research methodology of the global female infertility diagnosis and treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global female infertility diagnosis and treatment market.
  • Insights about market determinants that are stimulating the global female infertility diagnosis and treatment market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Female Infertility Diagnosis and Treatment Market
  • Recovery Scenario of Global Female Infertility Diagnosis and Treatment Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight and Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key CompanyAnalysis
    • 3.1.1. Bayer AG
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Church & Dwight Co. Inc
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Genea Ltd.
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Pfizer Inc
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Vitrolife Sweden AB
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Female Infertility Diagnosis and Treatment Market by Diagnosis
    • 4.1.1. Ovulation Testing
    • 4.1.2. Hysterosalpingography (HSG)
    • 4.1.3. Hysteroscopy
    • 4.1.4. Imaging Testing
    • 4.1.5. Ovarian Reserve Testing
    • 4.1.6. Hormonal Level Testing
    • 4.1.7. Genetic Testing
    • 4.1.8. Others (Laparoscopy)
  • 4.2. Global Female Infertility Diagnosis and Treatment Market by Treatment
    • 4.2.1. Drugs
    • 4.2.2. Surgery
    • 4.2.3. Intrauterine Insemination (IUI)
    • 4.2.4. Assisted Reproductive Technology (ART)
  • 4.3. Global Female Infertility Diagnosis and Treatment Market by End-User
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Homecare
    • 4.3.3. Pathology and Diagnostic Centers

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Cook Group Inc.
  • 6.2. Eli Lilly & Co.
  • 6.3. Esco Group
  • 6.4. Fairhaven Health
  • 6.5. Ferring B.V.
  • 6.6. Fujifilm Irvine Scientific, Inc.
  • 6.7. GlaxoSmithKline Plc.
  • 6.8. Merck KGaA
  • 6.9. Princeton BioMeditech Corp.
  • 6.10. Tempest Therapeutics, Inc.

LIST OF TABLES

  • 1. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028($ MILLION)
  • 2. GLOBAL OVULATION TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL HYSTEROSALPINGOGRAPHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL HYSTEROSCOPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL IMAGING TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL OVARIAN RESERVE TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL HORMONAL LEVEL TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 11. GLOBAL DRUGS FOR FEMALE INFERTILITY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL SURGERY FOR FEMALE INFERTILITY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL INTRAUTERINE INSEMINATION (IUI) FOR FEMALE INFERTILITY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY (ART) FOR FEMALE INFERTILITY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 16. GLOBAL FEMALE INFERTILITY TREATMENT IN HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. GLOBAL FEMALE INFERTILITY TREATMENT IN HOMECARE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 18. GLOBAL FEMALE INFERTILITY IN PATHOLOGY AND DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 19. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY,2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 21. NORTH AMERICAN FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 22. NORTH AMERICAN FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 23. NORTH AMERICAN FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 24. EUROPEAN FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 25. EUROPEAN FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 26. EUROPEAN FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 27. EUROPEAN FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 29. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 30. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 31. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 34. REST OF THE WORLD FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)

 

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET, 2021-2028 (%)
  • 4. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SHARE BY DIAGNOSIS, 2021 VS 2028 (%)
  • 5. GLOBAL OVULATION TESTING MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL HYSTEROSALPINGOGRAPHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL HYSTEROSCOPY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL IMAGING TESTING MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL OVARIAN RESERVE TESTING MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL HORMONAL LEVEL TESTING MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL GENETIC TESTING MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL OTHER DIAGNOSIS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SHARE BY TREATMENT, 2021 VS 2028 (%)
  • 14. GLOBAL DRUGS FOR FEMALE INFERTILITY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBALSURGERY FOR FEMALE INFERTILITY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL INTRAUTERINE INSEMINATION (IUI) FOR FEMALE INFERTILITY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 17. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT IN ANALGESIA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY (ART) FOR FEMALE INFERTILITY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 19. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SHARE BY END-USER, 2021 VS 2028 (%)
  • 20. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT IN HOSPITALS AND CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 21. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT IN HOMECARE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 22. GLOBAL FEMALE INFERTILITY DIAGNOSIS AND TREATMENT IN PATHOLOGY AND DIAGNOSTIC CENTERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 23. US FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CANADA FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. UK FEMALE INFERTILITY DIAGNOSIS AND TREATMEN T MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. FRANCE FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. GERMANY FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. ITALY FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. SPAIN FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. REST OF EUROPE FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. INDIA FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. CHINA FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. JAPAN FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 34. SOUTH KOREA FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 35. REST OF ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 36. REST OF THE WORLD FEMALE INFERTILITY DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)